Imricor Medical Systems, Inc. logo

Imricor Medical Systems, Inc. (IMR)

Market Closed
ASX ASX
253.97M Market Cap
- P/E Ratio
- Div Yield
567,409 Volume
-0.11 Eps
Want to track IMR and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

Summary

IMR is not paying dividends to its shareholders.
The last earnings report, released on Feb 25, 2026, exceeded the consensus estimates by 0%. On average, the company has fell short of earnings expectations by -0.0133%, based on the last three reports.
Imricor Medical Systems, Inc. has completed 1 stock splits, with the recent split occurring on Feb 05, 2024.
The company's stock is traded on 2 different exchanges and in various currencies, with the primary listing on ASX (AUD).

Imricor Medical Systems, Inc. (IMR) FAQ

On which exchange is it traded?

Imricor Medical Systems, Inc. is listed on ASX.

What is its stock symbol?

The ticker symbol is IMR.

Does it pay dividends? What is the current yield?

It does not pay dividends to its shareholders.

What is its market cap?

As of today, the market cap is 253.97M.

Has Imricor Medical Systems, Inc. ever had a stock split?

Imricor Medical Systems, Inc. had 1 splits and the recent split was on Feb 05, 2024.

Imricor Medical Systems, Inc. Profile

Health Care Equipment & Supplies Industry
Healthcare Sector
Mr. Steven Wedan CEO
ASX Exchange
AU0000054942 ISIN
United States Country
- Employees
- Last Dividend
5 Feb 2024 Last Split
- IPO Date

Overview

Imricor Medical Systems, Inc. is a pioneering company in the field of medical devices, specifically focusing on products that are compatible with magnetic resonance imaging (MRI) for cardiac catheter ablation procedures. The company has made significant strides since its inception in 2006 and is based out of Burnsville, Minnesota, USA. Their groundbreaking work revolves around the development, manufacture, sale, and distribution of innovative MRI-compatible tools that aim to improve the safety, efficiency, and outcomes of cardiac procedures. Additionally, Imricor is involved in contract research and licenses its advanced intellectual property for use in implantable devices, showcasing their versatility and commitment to advancing cardiac care.

Products and Services

Imricor Medical Systems, Inc. has developed a comprehensive range of products aimed at enhancing cardiac catheter ablation procedures with the unique advantage of MRI compatibility.

  • Advantage-MR EP Recorder/Stimulator System: This system represents a cornerstone in Imricor’s product line. It functions as an electrophysiology (EP) recording system and cardiac stimulator specifically designed for use in MRI environments. The Advantage-MR permits real-time procedural monitoring and pacing capabilities, thus offering unprecedented precision and safety during catheter ablation procedures.
  • Vision-MR Ablation Catheter: Specifically indicated for the treatment of type I atrial flutter, the Vision-MR Ablation Catheter brings forth a new era in cardiac ablation therapy. This catheter is designed for direct use within MRI fields, allowing for enhanced visualization of the cardiac anatomy and ablation sites, which, in turn, can lead to improved procedure outcomes and reduced recurrence rates.
  • Vision-MR Dispersive Electrode: Complementing the ablation catheter, this electrode is essential for minimizing eddy currents that are induced on conductive pads during MR scanning. Its use is crucial for ensuring patient safety and the accuracy of MRI-guided procedures, showcasing Imricor’s dedication to comprehensive care in cardiac interventions.

Beyond these innovative products, Imricor actively engages in contract research and intellectual property licensing, broadening the impact of their technological advancements into other areas of implantable medical devices. This multifaceted approach underlines their commitment to enhancing medical procedures and outcomes for patients globally.

Contact Information

Address: 400 Gateway Boulevard
Phone: 952 818 8400